Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080080 · ClinicalTrials.gov registry record · Phase 2
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Point Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00080080 is a Phase 2 study that has completed, run by Point Therapeutics.
The verdict
NCT00080080, a Phase 2 study, has completed, sponsored by Point Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.
Interventions
- DRUG Docetaxel
- DRUG talabostat (PT-100) tablets
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080080
The ClinicalTrials.gov registry entry for NCT00080080 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00080080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080080 about?
NCT00080080 is a clinical study titled "Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer". The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.
What is the current status of trial NCT00080080?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00080080?
The interventions under investigation include: Docetaxel (DRUG), talabostat (PT-100) tablets (DRUG).
Who is sponsoring clinical trial NCT00080080?
This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.